PKC
Protein Kinase C Alpha (PKCα) is a serine/threonine kinase involved in diverse cellular processes including proliferation, differentiation, and apoptosis. It plays a critical role in signal transduction pathways downstream of G-protein-coupled receptors and receptor tyrosine kinases[1]. PKCα regulates cell survival and growth through activation of the MAPK/ERK and PI3K/AKT pathways[2]. In cancer, PKCα is often overexpressed and contributes to tumor progression, particularly in breast and prostate cancers[3]. It also modulates vascular smooth muscle contraction and endothelial function, implicating it in cardiovascular diseases. Notably, PKCα exhibits distinct functions compared to other PKC isoforms due to its unique subcellular localization and substrate specificity[4]. Targeting PKCα with selective inhibitors such as Gö6976 has shown therapeutic potential in preclinical models of cancer and inflammatory disorders[5].
References:
- [1]. Lee MJ, et al. Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial. Lancet HIV. 2026 May 27:S2352-3018(26)00059-7. [Content Brief]
- [2]. Wolf S, et al. Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas. Oncogene. 2013 Jun 20;32(25):3028-38. [Content Brief]
- [3]. Ali SR, et al. Nerve Density and Neuronal Biomarkers in Cancer. Cancers (Basel). 2022 Oct 1;14(19):4817. [Content Brief]
- [4]. Kim JY, et al. The induction of STAT1 gene by activating transcription factor 3 contributes to pancreatic beta-cell apoptosis and its dysfunction in streptozotocin-treated mice. Cell Signal. 2010 Nov;22(11):1669-80. [Content Brief]
- [5]. Ciglenecki I, et al. Low sensitivity of the fourth-generation antigen/antibody HIV rapid diagnostic test Determine™ HIV Early Detect for detection of acute HIV infection at the point of care in rural Eswatini: a diagnostic accuracy study. J Int AIDS Soc. 2025 Jul;28(7):e26517. [Content Brief]
All Product Categories
-
PKC Related Products (383)
Related Products (383)
-
Prkcq Rat Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS11139Prkcq Rat Pre-designed siRNA Set A contains three designed siRNAs for Prkcq gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
GSK-943949A
0 ImagesCat. No.: HY-130305ACAS No.: 913640-58-1GSK-943949A is a PRK1 inhibitor with an IC50 of 40.0 nM. GSK-943949A is applicable to research related to prostate cancer.
-
N-Desmethyltamoxifen hydrochloride (Standard)
0 ImagesN-Desmethyltamoxifen (hydrochloride) (Standard) is the analytical standard of N-Desmethyltamoxifen (hydrochloride). This product is intended for research and analytical applications. N-Desmethyltamoxifen hydrochloride is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen hydrochloride is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation[1][2][3].
-
Prkce Rat Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS11127Prkce Rat Pre-designed siRNA Set A contains three designed siRNAs for Prkce gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
Prkcd Mouse Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS11123Prkcd Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prkcd gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
Chrysosplenol C
0 ImagesCat. No.: HY-N13747CAS No.: 23370-16-3Chrysosplenol C is a type of flavonoid compound. Chrysosplenol C selectively activates cardiac myosin ATPase, with its EC50 being 45 µM. Chrysosplenol C enhances the release of intracellular calcium ions by activating protein kinase C (PKC), thereby increasing the contractility of rat ventricular muscle cells. Chrysosplenol C can be used in the research of heart failure.
-
Protein Kinase C β Peptide
0 ImagesCat. No.: HY-P3841CAS No.: 309247-50-5Protein Kinase C (beta) Peptide is a peptide fragment of Protein Kinase Cβ. Protein Kinase Cβ is related with hyperglycemia decreases endothelium-derived nitric oxide. Inhibition of Protein kinase Cβ prevents the reduction in endothelium-dependent vasodilation induced by acute hyperglycemia.
-
(S)-Ro 32-0432 free base
0 ImagesCat. No.: HY-108601CAS No.: 151342-35-7(S)-Ro 32-0432 free base is a potent, selective, ATP-competitive and orally active PKC inhibitor. The IC50 values of (S)-Ro 32-0432 free base for PKCα, PKCβI, PKCβII, PKCγ and PKCε are 9.3 nM, 28 nM, 30 nM, 36.5 nM and 108.3 nM, respectively. (S)-Ro 32-0432 free base is also a selective G protein-coupled receptor kinase 5 (GRK5) inhibitor. (S)-Ro 32-0432 free base prevents T-cell activation and has the potential for chronic inflammatory and autoimmune diseases research.
-
PRKCQ Human Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS11137PRKCQ Human Pre-designed siRNA Set A contains three designed siRNAs for PRKCQ gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
1,2-Didecanoylglycerol
0 ImagesCat. No.: HY-115769CAS No.: 17863-69-31,2-Didecanoylglycerol, a synthetic diacylglycerol, is metabolized by platelets to 1,2-didecanoylphosphatidic acid (PA10) and activates protein kinase C (PKC).
-
PKCδ Peptide Substrate acetate
0 ImagesCat. No.: HY-P3818APurity: 98.30%PKCδ Peptide Substrate acetate is a highly selective peptide substrate targeting PKCδ. PKCδ Peptide Substrate acetate can only be efficiently catalyzed for phosphorylation modification by PKCδ, and Thr431 is the sole phosphorylation site. PKCδ Peptide Substrate acetate binds to the catalytic pocket of PKC in a competitive manner, but exhibits no PKC agonistic or inhibitory activity. PKCδ Peptide Substrate acetate is a dedicated biochemical probe for the quantitative detection of PKCδ in vitro, and can be used for studies on PKCδ-related pathways.
-
ɛPKC(85–92),Myristoylated
0 ImagesCat. No.: HY-P5877CAS No.: 1072301-79-1
-
Prkci Mouse Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS11135Prkci Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prkci gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
Sangivamycin (Standard)
0 ImagesCat. No.: HY-118384RCAS No.: 18417-89-5Synonyms: NSC 65346 (Standard); BA-90912 (Standard)Sangivamycin (Standard) is the analytical standard of Sangivamycin. This product is intended for research and analytical applications. Sangivamycin (NSC 65346), a nucleoside analog, is a potent inhibitor of protein kinase C (PKC) with an Ki of 10 μM. Sangivamycin has potent antiproliferative activity against a variety of human cancers[1][2].
-
MDL 27032
0 ImagesCat. No.: HY-105517CAS No.: 110124-55-5
-
Prkca Mouse Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS11117Prkca Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prkca gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
Myricitrin (Standard)
0 ImagesMyricitrin (Standard) is the analytical standard of Myricitrin. This product is intended for research and analytical applications. Myricitrin, a naturally occurring flavonoid, is an orally active nitric oxide (NO) and PKC inhibitor. Myricitrin has central nervous system activity, including anxiolytic-like action. Myricitrin possesses antioxidant, anti-inflammatory, antifibrotic and anti-malarial effects.
-
O-Desmethyl midostaurin-13C6
0 ImagesCat. No.: HY-W751181Synonyms: CGP62221-13C6; O-Desmethyl PKC412-13C6O-Desmethyl midostaurin-13C6 (CGP62221-13C6; O-Desmethyl PKC412-13C6) is the 13C-labeled O-Desmethyl Midostaurin (HY-129491). O-Desmethyl Midostaurin (CGP62221; O-Desmethyl PKC412) is the active metabolite of Midostaurin (HY-10230) via cytochrome P450 liver enzyme metabolism. O-Desmethyl Midostaurin can be used as an indicator for Midostaurin metabolism in vivo. Midostaurin is a multi-targeted protein kinase inhibitor?with?IC50?ranging from 22-500 nM.
-
BTK-IN-50
0 ImagesCat. No.: HY-184940BTK-IN-50 is a covalent BTK inhibitor with an IC50 of 6 nM. BTK-IN-50 blocks collagen-induced platelet aggregation by inhibiting the GPVI-mediated BTK-PLCγ2-PKC signaling cascade, and attenuates CRP-XL-induced phosphorylation of BTK, PLCγ2 and PKC substrates in platelets. BTK-IN-50 can be used for research related to thrombosis.
